MCM
TBPH icon

Manchester Capital Management’s Theravance Biopharma TBPH Stock Holding History

Manchester Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-999
Closed -$15K – 844
2014
Q4 		$15K Hold
999
– – ﹤0.01% 923
2014
Q3 		$23K Buy
+999
New +$29K ﹤0.01% 864

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Manchester Capital Management's TBPH Position: Q1 2015 in Review

Manchester Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2015, closing a stake of 999 shares — an estimated $15K sold.

Manchester Capital Management first reported a position in TBPH in Q3 2014 and held it in 2 quarters. The position peaked at $23K in Q3 2014. 89 funds tracked by Wall St. Rank hold TBPH as of Q1 2015.

  • Manchester Capital Management reported no remaining Theravance Biopharma position as of Q1 2015 after selling out during the quarter.
  • Manchester Capital Management sold 999 Theravance Biopharma shares in Q1 2015, an estimated $15K.
  • Manchester Capital Management first reported a position in Theravance Biopharma in Q3 2014 and held it in 2 quarters.
  • Manchester Capital Management's Theravance Biopharma position peaked at $23K in Q3 2014.
  • 89 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2015.

Based on Manchester Capital Management's 13F filing for Q1 2015, filed 7 May 2015.